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Abstract: Starting from a chiral methylenecyclopropane building
block, readily obtained by enzymatic desymmetrization of a meso-
diol, two types of methylenecyclopropane analogues of nucleosides
were synthesized. The first type of nucleosides was obtained from
the direct coupling of the chiral building block with 6-chloropurine
under Mitsunobu reaction conditions followed by the functionaliza-
tion of the purine base. The second type of nucleosides featured a
Curtius rearrangement as the key step and the uracil heterocycle
was then constructed by a linear methodology. These derivatives
were evaluated as potential agents against important viral patho-
gens. None of the new compounds had significant antiviral activity
at a concentration of 100 μg/mL, which was the highest concentra-
tion tested.
Key words: stereoselective synthesis, Curtius rearrangement, car-
bocyclic nucleosides, methylenecyclopropane carbonucleosides,
antiviral agents
Nucleoside analogues represent an important class of
therapeutic agents and show a remarkable wide spectrum
of antiviral chemotherapy.1 Among them, carbocyclic nu-
cleosides are nucleoside analogues in which a carbon
atom has replaced the oxygen atom of the furanose ring.
They have been extensively studied including carbovir,2
abacavir3 (Ziagen®), and some cyclopentanic nucleo-
sides.4 In fact, they can display similar biological activity
while presenting better stability as they are not prone to
the action of the glycosylases that cleave the glycosidic
bond of the natural nucleosides. As an example, entecavir5
(Baraclude®), a carbanucleoside possessing a methylene-
cyclopentane skeleton, has been approved for the treat-
ment of HBV infection (Figure 1). Moreover, in the
course of the synthesis of novel antiviral nucleoside ana-
logues, structural modifications of the heterocyclic bases
and/or modifications on the sugar moiety have been at-
tempted.6 As a consequence, novel nucleosides containing
a cyclopropane moiety have been found to have potent an-
tiviral activity. Thus, methylenecyclopropane analogues
of nucleosides,7 such as synadenol8 and cyclopropavir,9
have been established as antiviral agents against β-herpes
viruses and γ-herpes viruses.10 In this paper, we report the
synthesis and biological evaluation, with full experimen-
tal details, of novel methylenecyclopropane analogues of
nucleosides.
Figure 1  The structures of entecavir (Baraclude®), synadenol, cyclo-
propavir, and the methylenecyclopropane nucleosides synthesized in
this work
We recently published a short paper on the synthesis and
the enzymatic desymmetrization of meso-diol11 1
(Scheme 1) that is used herein for the synthesis of novel
types of methylenecyclopropane nucleosides. The synthe-
sis of meso-diol 1 was accomplished in 64% yield in three
steps starting from 2,2-dimethyl-4,7-dihydro-1,3-dioxe-
pin, which is easily prepared according to a literature pro-
cedure.12 First, addition of methylchlorocarbene,13
generated in situ from 1,1-dichloroethane and butyllithi-
um in hexanes at –35 °C, to the dioxepin gave a 4:1 (by 1H
NMR) trans/cis mixture of the expected diastereomeric
chlorocyclopropanes. Then, dehydrochlorination of the
chlorocyclopropanes with potassium tert-butoxide in di-
methyl sulfoxide afforded methylenecyclopropane 2 in
76% yield, which was hydrolyzed with 2 M hydrochloric
acid to give the diol 1 in 81% yield.
After screening commercial lipases, (–)-4 was obtained on
a large scale in 86% yield and an enantioselectivity of
98% ee by using lipase AK (from Pseudomonas fluores-
cens, PFL) and vinyl acetate in diisopropyl ether (Scheme
2). The high enantiomeric purity of (–)-4 was determined
by HPLC (Figure 2). Moreover, the stereostructure of 4
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was secured by single crystal X-ray diffraction of the cor-
responding camphanate ester derivative used. As depicted
in Scheme 2, the reaction of (–)-4 with (1S,4R)-camphanic
chloride14 afforded the derivative (–)-5 in 91% yield,
which was obtained as an oil. To solve this problem we
performed the selective hydrolysis of the acetate group.
Thus, treatment of (–)-5 with potassium carbonate in
methanol afforded the crystalline alcohol (+)-6 in 86%
yield. The ORTEP view of (+)-6 is shown in Figure 2.15
The synthesis of the enantiomer (+)-4, by desymmetriza-
tion of diacetate 3, was also accomplished. Thus, treat-
ment of 1 with acetic anhydride and pyridine gave the
meso-diacetate 3 in 91% yield. Treatment of 3 with PFL
in the presence of butanol in diisopropyl ether afforded
(+)-4 in 82% yield and with >98% ee. The high enantio-
meric purity of (+)-4 was also checked by HPLC (Figure
2). This methodology provides a very simple and practical
tool to access the two enantiomers of a versatile building
block used to synthesize the target nucleosides, both on a
large scale and with high enantiomeric excess.
The syntheses of methylenecyclopropane analogues of
nucleosides are outlined in Scheme 3. Derivative (–)-4
was treated with 6-chloropurine in the presence of diiso-
propyl azodicarboxylate (DIAD) and triphenylphosphine
to give the corresponding chloropurine (+)-7 in 86%
yield.16 One-pot ammonolysis and deprotection of the
acetyl group of (+)-7 by treatment with saturated metha-
nolic ammonia solution at 100 °C in a stainless steel
pressure vessel for 10 hours provided 92% yield of amino-
purine (–)-8. Alternatively, treatment of (+)-7 with cyclo-
propylamine followed by cleavage of the acetyl protecting
group with methanolic ammonia produced the target
aminopurine (–)-9 in 89% yield for two steps.
The methodology for the synthesis of another type of
methylenecyclopropane analogue of nucleosides used the
Curtius reaction17 as a key step in order to remove a car-
bon atom and therefore to attach the heterocyclic base di-
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Figure 2  Chiral HPLC diagrams of (±)-4, (–)-4 and (+)-4 and ORTEP view of chiral camphanate derivative (+)-6
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rectly to the carbasugar (Scheme 4). Thus, Jones’ reagent
was employed to oxidize the alcohol (–)-4 in acetone at
0 °C to the corresponding carboxylic acid (–)-10 in 91%
yield.18 Direct transformation of carboxylic acid to the
acyl azide (+)-11 with diphenylphosphoryl azide and tri-
ethylamine in dichloromethane failed and no reaction was
observed.19 The carboxylic acid (–)-10 was then convert-
ed into the acid chloride with oxalyl chloride at 0 °C and
then to the acyl azide (+)-11 by using sodium azide in a
water–acetone mixture.20 Then, Curtius rearrangement of
acyl azide (+)-11 to the corresponding isocyanate 12 was
conducted in benzene, but the temperature should be kept
below 75 °C as we observed decomposition of thus
formed isocyanate derivative and this resulted in lower
yields. As isocyanate 12 is unstable, the addition under
neutral, acidic, and basic conditions of water,21 metha-
nol,17b or butanol22 were attempted directly with the crude
isocyanate 12, but all these reactions were unsuccessful
and led to decomposition of the starting material.
Fortunately, addition of tert-butyl alcohol to the crude iso-
cyanate 12 at room temperature, followed by heating of
the reaction mixture at 75 °C gave the carbamate (+)-13 in
75% yield for the two steps after purification by flash
chromatography on silica gel.23 Then, the simultaneous
deprotection of the carbamate and acetate functions of
(+)-13 was conducted in acidic conditions to afford the
hydrochloride salt of amine 14 in 85% yield.19a After the
completion of the synthesis of the carbocyclic aminosugar
bearing the methylenecyclopropane moiety, the final
stage involved the introduction of the heterocyclic base.
All attempts to provide methylenecyclopropane ana-
logues of nucleosides by construction of the purine base
failed. Indeed, the condensation of 14 with 4,6-dichloro-
pyrimidin-2-amine in the presence of diisopropylethyl-
amine in butanol at reflux did not give the expected
pyrimidine intermediate.24 As a consequence, we investi-
gated the synthesis of pyrimidine heterocyclic base as the
precursor needed to react with the carbosugar is much
more reactive, and so the coupling reaction could be real-
ized under mild conditions. Then, the uracil base was con-
structed with a previously adapted methodology.25 Ethyl
vinyl ether was reacted with chlorocarbonyl isocyanate
and the reaction mixture was treated with triethylamine to
provide the highly reactive isocyanate intermediate. Con-
densation at –40 °C of this isocyanate with the hydrochlo-
ride salt 14 in the presence of triethylamine gave the
preformed uracil base (+)-15. Finally, treatment of the
(+)-15 with 0.5 M sulfuric acid provided the uracil deriv-
ative (+)-16. This two-step sequence gave (+)-16 in 75%
yield from 14 after purification by column chromatogra-
phy on silica gel. The enantioselective synthesis of the
methylenecyclopropane (+)-16 with a uracil moiety as
heterocyclic base was accomplished in eight steps in 34%
overall yield from the chiral building block (–)-4.
Compounds 8, 9, and 16 were evaluated for their antiviral
activity in human embryonic lung (HEL) cells [herpes
simplex virus type 1 (HSV-1, strain KOS), herpes simplex
virus type 2 (HSV-2, strain G), vaccinia virus, vesicular
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stomatitis virus, thymidine kinase-deficient (TK-) HSV-1
(strain KOS, ACVr)], Vero cells (parainfluenza type 3 vi-
rus, reovirus type 1, Sindbis virus, Coxsackie B4 virus,
Punta Toro virus), HeLa cells (vesicular stomatitis virus,
Coxsackie B4 virus, respiratory syncytial virus), and Ma-
din Darby canine kidney cells (influenza A H3N2, influ-
enza A H1N1 and influenza B). In no case was significant
antiviral activity or cytotoxicity witnessed at a concentra-
tion of 100 μg/mL, which was the highest concentration
tested.
In summary, the enantioselective synthesis of methylene-
cyclopropane analogues of nucleosides 8, 9, and 16 was
achieved starting from acetate 4 obtained by desymmetri-
zation of a meso-diol. Thus, the nucleosides were synthe-
sized by a direct coupling of the chiral building block
under Mitsunobu conditions or by Curtius rearrangement
followed by a linear methodology to construct the uracil
heterocycle. Synthesized compounds were tested as po-
tential antiviral agents; none of these compounds showed
antiviral activity.
All air and/or H2O sensitive reactions were performed under an ar-
gon atmosphere with dry, freshly distilled solvents using standard
syringe-cannula/septa techniques; all glassware was oven-dried
(80 °C) and/or carefully dried in line with a flameless heat gun. All
solvents were distilled under an argon atmosphere: THF from a blue
soln of Na/benzophenone ketyl radical prior to use; CH2Cl2 and
DMF from CaH2, benzene and Et2O from LiAlH4. Routine monitor-
ing of reactions was performed using Merck Silica gel 60 F254, alu-
minum-supported TLC plates; spots were visualized using UV light
and ethanolic acidic p-anisaldehyde soln or ethanolic phosphomo-
lybdic soln, followed by heating. Purification by column chroma-
tography was performed with silica gel 60 (230–400 mesh) and
gradients of Et2O–petroleum ether or CH2Cl2–MeOH, unless other-
wise stated. 1H and 13C NMR spectra were recorded in CDCl3,
MeOH-d4, or DMSO-d6 on a Bruker Avance DPX-300 spectrome-
ter; residual nondeuterated solvent was used as internal reference.
Optical rotations were measured on a Perkin-Elmer 241 polarime-
ter. Melting points are uncorrected. HRMS were performed using a
SYNAPT G2 HDMS (Waters) mass spectrometer equipped with a
pneumatically assisted atmospheric pressure ionization. The sample
was ionized in positive mode electrospray under the following con-
ditions: electrospray voltage (ISV): 2800 V; orifice voltage (OR):
20 V; nebulizing gas flow (N2): 800 L/h. The mass spectrum was
obtained using a time of flight analyzer (TOF). The measure was re-
alized in triplicate, with double internal standardization. The sample
was dissolved in CH2Cl2 (450 μL) then diluted (dilution factor
1/103) in a methanolic soln of NH4OAc (3 mM). The sample soln
was infused in the ionization source at a 10 μL/min flow rate. Lipase
AK (from Pseudomonas fluorescens, PFL) was gifted by Amano
Pharmaceutical (Nagoya, Japan).
4,4-Dimethyl-8-methylene-3,5-dioxabicyclo[5.1.0]octane (2)
A soln of 2,2-dimethyl-4,7-dihydro-1,3-dioxepin (20.0 g, 156
mmol) and 1,1-dichloroethane (13.0 mL, 156 mmol) in anhyd Et2O
(100 mL) was cooled at –35 °C. Then, 2.5 M BuLi in hexane (61.6
mL, 156 mmol) was added to the mixture over a period of 3 h,
during which time the reaction temperature was maintained between
–40 and –35 °C. The mixture was stirred at –35 °C for 14 h, and
then it was warmed to 0 °C and quenched with H2O. The aqueous
layer was extracted with Et2O, and the combined Et2O extracts were
dried, filtered, and concentrated. The oily residue was used in the
next reaction without further purification. 
To this crude product (26.7 g, 140 mmol) dissolved in anhyd DMSO
(100 mL), t-BuOK (15.3 g, 140 mmol) was added and the resulting
mixture was stirred at 70 °C for 1 h. The soln was then cooled to r.t.,
diluted with brine, followed by repeated extraction with Et2O. The
combined organic layers were dried (anhyd MgSO4), filtered, and
concentrated. The crude product was purified by flash chromatog-
raphy to give methylenecyclopropane 2 (18.3 g, 76%) as a colorless
oil.
IR (neat): 3046, 1651, 1244, 1132 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.43 (m, 2 H), 4.15–4.04 (m, 2 H),
3.84–3.71 (m, 2 H), 1.89–1.82 (m, 2 H), 1.37 (s, 3 H), 1.50 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 137.4 (C), 103.1 (CH2), 102.6 (C),
61.3 (2 CH2), 24.5 (2 CH), 20.5 (2 CH3).
HRMS (ESI): m/z [M + Na]+ calcd for C9H14NaO2: 177.0886;
found: 177.0880.
[2-(Hydroxymethyl)-3-methylenecyclopropyl]methanol (1)
A soln of compound 2 (10.0 g, 64.9 mmol) in THF (100 mL) was
cooled at 0 °C, and aq 2 M HCl soln (50 mL) was added. The result-
ing soln was stirred for 2 h at r.t. The mixture was then cooled, neu-
tralized with Amberlyst IRA-67, filtered, and concentrated under
reduced pressure. Purification of the residue by column chromatog-
raphy (silica gel) gave the meso-diol 1 (6.01 g, 81%) as a colorless
oil.
IR (neat): 3379, 3076, 1262, 1158 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.36 (m, 2 H), 4.05–3.97 (m, 2 H),
3.81 (m, 2 H), 3.42–3.27 (m, 2 H), 2.06–2.00 (m, 2 H).
13C NMR (75 MHz, CDCl3): δ = 135.3 (C), 105.1 (CH2), 60.3 (2
CH2), 22.5 (2 CH).
HRMS (ESI): m/z [M + Na]+ calcd for C6H10NaO2: 137.0573;
found: 137.0573.
(–)-(1R,2S)-2-(Hydroxymethyl)-3-methylenecyclopropylmeth-
yl Acetate [(–)-4]
The meso-diol 1 (6.00 g, 52.6 mmol), PFL (600 mg), and vinyl
acetate (10 mL) in i-Pr2O (50 mL) were magnetically stirred at r.t.
(TLC monitoring). After 1 h, the mixture was filtered, the solvent
was removed in vacuo and the residue was purified by column chro-
matography (silica gel) to give monoacetate (–)-4 (7.09 g, 86%) as
a colorless oil.
[α]D25 –5.7 (c 1.0, CHCl3).
IR (neat): 3381, 3061, 1748, 1259, 1152 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.45 (s, 2 H), 4.45 (dd, J = 12.4,
5.1 Hz, 1 H), 3.90 (dd, J = 12.3, 7.9 Hz, 1 H), 3.88 (d, J = 12.4 Hz,
1 H), 3.45 (dd, J = 12.3, 9.6 Hz, 1 H), 2.23 (br s, 1 H), 2.12–2.05 (m,
1 H, partially overlapped), 2.09 (s, 3 H), 2.03–1.96 (m, 1 H).
13C NMR (75 MHz, CDCl3): δ = 171.2 (C), 133.5 (C), 105.6 (CH2),
62.5 (CH2), 60.6 (CH2), 23.2 (CH), 21.2 (CH), 18.9 (CH3).
HRMS (ESI): m/z [M + H]+ calcd for C8H13O3: 157.0859; found:
157.0857.
(–)-2-(Acetoxymethyl)-3-methylenecyclopropylmethyl 4,7,7-
Trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate 
[(–)-5]
To a soln of (–)-4 (100 mg, 0.64 mmol) and DMAP (11.7 mg, 0.1
mmol) in pyridine (15 mL) at 5 °C under an argon atmosphere, was
added (–)-(1S,4R)-camphanic acid chloride (160 mg, 0.70 mmol).
The cooling bath was removed and the soln was stirred at r.t. (TLC
monitoring) and the reaction was complete within 1 h. The mixture
was diluted with CH2Cl2 and then it was sequentially washed with
H2O, aq 1 M HCl soln, aq 1 M NaHCO3 soln, and brine. The organic
layer was dried (anhyd MgSO4), filtered, and concentrated in vacuo.
The crude mixture was subjected to column chromatography to af-
ford (–)-5 (196 mg, 91%) as a colorless oil.
[α]D25 –13.4 (c 1.0, CHCl3).
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IR (neat): 3058, 1741, 1728, 1174 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.47 (s, 2 H), 4.42 (dd, J = 11.7,
6.8 Hz, 1 H), 4.38 (dd, J = 11.7, 5.1 Hz, 1 H), 4.10 (dd, J = 11.7, 8.2
Hz, 1 H), 3.91 (dd, J = 11.7, 8.6 Hz, 1 H), 2.43 (ddd, J = 12.1, 8.6,
4.6 Hz, 1 H), 2.03 (s, 3 H), 2.06–1.90 (m, 4 H), 1.63 (ddd, J = 12.3,
9.3, 4.6 Hz, 1 H), 1.07 (s, 3 H), 1.03 (s, 3 H), 0.94 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 178.1 (C), 170.9 (C), 167.5 (C),
132.8 (C), 106.3 (CH2), 91.1 (C), 63.6 (CH2), 62.0 (CH2), 54.8 (C),
54.2 (C), 30.7 (CH2), 28.9 (CH2), 21.0 (CH3), 19.1 (CH), 18.6 (CH),
16.8 (2 CH3), 9.7 (CH3).
HRMS (ESI): m/z [M + H]+ calcd for C18H25O6: 337.1646; found:
337.1646.
(+)-2-(Hydroxymethyl)-3-methylenecyclopropylmethyl 4,7,7-
Trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate 
[(+)-6]
To a soln of (–)-5 (100 mg, 0.30 mmol) in MeOH (10 mL) was add-
ed K2CO3 (50.0 mg, 0.40 mmol). The mixture was stirred for 24 h
at r.t., and then it was concentrated to remove MeOH, diluted with
Et2O, filtered, and concentrated in vacuo. Purification of the residue
by flash chromatography gave (+)-6 (76 mg, 86%) as a solid. Re-
crystallization in Et2O–pentane gave (+)-6 as single crystals, suit-
able for X-ray diffraction; mp 81–83 °C.
[α]D25 +9.0 (c 1.0, CHCl3).
IR (KBr): 3369, 3026, 1784, 1749, 1731, 1172 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.44 (s, 2 H), 4.52 (m, 1 H), 4.08
(dd, J = 11.8, 9.1 Hz, 1 H), 3.84 (br d, J = 13.5 Hz, 1 H), 3.47 (dd,
J = 12.1, 8.9 Hz, 1 H), 2.49 (br s, 1 H), 2.32 (dd, J = 8.9, 4.6 Hz, 1
H), 2.01–1.92 (m, 4 H), 1.62 (ddd, J = 12.3, 9.2, 4.5 Hz, 1 H), 1.11
(s, 3 H), 1.02 (s, 3 H), 0.93 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 177.8 (C), 167.5 (C), 133.4 (C),
105.6 (CH2), 91.0 (C), 63.9 (CH2), 60.3 (CH2), 54.7 (C), 54.3 (C),
30.7 (CH2), 28.9 (CH2), 22.9 (CH), 18.3 (CH), 16.7 (2 CH3), 9.7
(CH3).
HRMS (ESI): m/z [M + H]+ calcd for C16H23O5: 295.3547; found:
295.3548.
2-(Acetoxymethyl)-3-methylenecyclopropylmethyl Acetate (3)
To a stirred soln of meso-diol 1 (1.00 g, 8.76 mmol) in pyridine (50
mL) was added Ac2O (2.00 mL, 18.4 mmol) and the mixture was
stirred for 24 h at r.t. The mixture was poured into H2O and extract-
ed with EtOAc. The combined organic layers were washed with aq
10% CuSO4 soln, H2O, and brine, and then dried (anhyd MgSO4).
Concentration of the organic layer in vacuo followed by purification
of the residue by column chromatography (silica gel) gave 3 (1.58
g, 91%) as a colorless oil.
IR (neat): 3039, 1779, 1261, 1171 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.48 (t, J = 2.2 Hz, 2 H), 4.48 (dd,
J = 11.1, 7.5 Hz, 2 H), 3.95 (dd, J = 11.1, 8.5 Hz, 2 H), 2.11 (br s, 8
H).
13C NMR (75 MHz, CDCl3): δ = 170.7 (2 C), 133.4 (C), 105.8
(CH2), 62.3 (2 CH2), 20.9 (2 CH), 18.8 (2 CH3).
HRMS (ESI): m/z [M + H]+ calcd for C10H15O4: 199.2261; found:
199.2263.
(+)-(1S,2R)-2-(Hydroxymethyl)-3-methylenecyclopropylmeth-
yl Acetate [(+)-4]
To a soln of diacetate 3 (1.00 g, 5.04 mmol) in i-Pr2O (50 mL) and
BuOH (10 mL) was added PFL (100.0 mg). The mixture was stirred
at r.t. for 18 h. Then, the mixture was filtered through a pad of
Celite. Concentration of the organic layer in vacuo followed by pu-
rification by column chromatography (silica gel) gave (+)-4. IR, 1H
NMR, 13C NMR, and HRMS data are identical with those described
for (–)-4. [α]D25 +5.9 (c 1.0, CHCl3).
(+)-(1R,2S)-2-(6-Chloropurin-9-ylmethyl)-3-methylenecyclo-
propylmethyl Acetate [(+)-7]
DIAD (379 μL, 1.87 mmol) was added dropwise to a soln of Ph3P
(504 mg, 1.87 mmol) in anhyd THF (15 mL) under an argon atmo-
sphere at 0 °C. The mixture was stirred for 30 min and then 6-chlo-
ropurine (297 mg, 1.87 mmol) was added. The mixture was stirred
for an additional 30 min and then a soln of alcohol (–)-4 (200 mg,
1.28 mmol) in anhyd THF (15 mL) was slowly added. The cooling
bath was removed and the mixture was stirred at r.t. for 12 h. The
volatiles were evaporated in vacuo and the resulting residue was pu-
rified by column chromatography to give the carbonucleoside (+)-7
(322 mg, 86%) as a foam.
[α]D25 + 13.0 (c 1.0, CHCl3).
IR (neat): 3029, 1758, 1241, 1136 cm–1.
1H NMR (300 MHz, CDCl3): δ = 8.68 (s, 1 H), 8.23 (s, 1 H), 5.52
(t, J = 2.0 Hz, 1 H), 5.43 (t, J = 2.0 Hz, 1 H), 4.50 and 3.84 (ABX,
J = 12.3, 10.2, 5.1 Hz, 2 H), 4.38 and 4.28 (ABX, J = 14.7, 8.5, 6.8
Hz, 2 H), 2.36–2.25 (m, 1 H), 2.16–2.07 (m, 1 H), 1.91 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 170.6 (C), 151.9 (CH), 151.8 (C),
150.9 (C), 145.0 (CH), 132.2 (C), 131.5 (C), 106.9 (CH2), 61.6
(CH2), 42.5 (CH2), 20.8 (CH), 19.4 (CH), 19.2 (CH3).
HRMS (ESI): m/z [M + H]+ calcd for C13H14N4O2Cl: 293.0800;
found: 293.0802.
(–)-(1R,2S)-[2-(6-Aminopurin-9-ylmethyl)-3-methylenecyclo-
propylmethyl]methanol [(–)-8]
A soln of (+)-7 (100 mg, 0.34 mmol) in sat. methanolic NH3 (20
mL) was heated at 100 °C for 10 h in a Parr stainless steel sealed re-
action vessel. Then, the reaction mixture was allowed to cool to r.t.
and concentrated in vacuo. The residue was purified by column
chromatography to give carbonucleoside (–)-8 (72.3 mg, 92%) as a
white solid; mp 170–172 °C.
[α]D25 –35.4 (c 1.0, MeOH).
IR (KBr): 3387, 3031, 1603, 1274, 1181 cm–1.
1H NMR (300 MHz, DMSO-d6): δ = 8.22 (s, 1 H), 8.17 (s, 1 H), 7.28
(s, 2 H), 5.41 (s, 1 H), 5.32 (s, 1 H), 5.04 (t, J = 5.3 Hz, 1 H), 4.30
and 4.21 (ABX, J = 14.7, 8.1, 6.4 Hz, 2 H), 3.78 (dt, J = 11.3, 5.4
Hz, 1 H), 3.46 (m, 1 H, partially overlapped), 2.16 (m, 1 H), 1.97
(m, 1 H).
13C NMR (75 MHz, DMSO-d6): δ = 156.0 (C), 152.3 (CH), 149.4
(C), 140.9 (CH), 135.3 (C), 118.7 (C), 104.4 (CH2), 58.5 (CH2),
40.8 (CH2), 22.8 (CH), 19.3 (CH).
HRMS (ESI): m/z [M + H]+ calcd for C11H14N5O: 232.2645; found:
232.2644.
(–)-(1R,2S)-{2-[6-(Cyclopropylamino)purin-9-ylmethyl]-3-
methylenecyclopropylmethyl}methanol [(–)-9]
A soln of (+)-7 (65.0 mg, 0.22 mmol) and cyclopropylamine (1.0
mL) in MeOH (5.0 mL) was stirred at r.t. for 12 h under argon. The
reaction mixture was allowed to cool to r.t. and concentrated in
vacuo. Then, the resulting residue was dissolved into sat. methano-
lic NH3 (15 mL) in a flask fitted with a rubber stopper at r.t. for 5 h.
After evaporation of the solvent in vacuo, the residue was purified
by column chromatography to give (–)-9 (53.6 mg, 89%) as a white
solid; mp 184–185 °C.
[α]D25 –26.4 (c 1.0, MeOH).
IR (KBr): 3406, 3017, 1598, 1249, 1173 cm–1.
1H NMR (300 MHz, MeOH-d4): δ = 8.26 (s, 1 H), 8.19 (s, 1 H), 5.46
(t, J = 2.0 Hz, 1 H), 5.37 (t, J = 2.0 Hz, 1 H), 4.37 and 4.23 (ABX,
J = 14.6, 8.2, 5.9 Hz, 2 H), 3.93 (dd, J = 12.1, 5.2 Hz, 1 H), 3.57 (dd,
J = 12.1, 9.3 Hz, 1 H), 2.97–2.90 (m, 1 H), 2.23–2.12 (m, 1 H),
2.11–2.01 (m, 1 H), 0.90–0.82 (m, 2 H), 0.66–0.59 (m, 2 H).
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13C NMR (75 MHz, MeOH-d4): δ = 157.0 (C), 153.4 (CH), 149.6
(C), 142.4 (CH), 135.5 (C), 120.4 (C), 105.4 (CH2), 60.2 (CH2),
42.5 (CH2), 24.6 (CH), 24.1 (CH), 20.7 (CH), 7.6 (2 CH2).
HRMS (ESI): m/z [M + H]+ calcd for C14H18ON5: 272.1506; found:
272.1505.
(–)-(1S,2R)-2-(Acetoxymethyl)-3-methylenecyclopropanecar-
boxylic Acid [(–)-10]
A soln of Jones reagent [prepared by mixing CrO3 (26.7 g) with
concd H2SO4 (23 mL), followed by dilution with H2O to a final vol-
ume of 100 mL] was added to a soln of alcohol (–)-4 (4.00 g, 25.6
mmol) in acetone (100 mL). Addition of Jones reagent (ca. 20 mL)
was continued at 0 °C until the reddish color persisted for at least 5
min. The resulting soln was stirred for a further 1 h at r.t., and the
excess oxidizing reagent was quenched with i-PrOH. The resulting
soln was then diluted with H2O followed by repeated extraction
with EtOAc. The combined organic phases were washed with 10%
aq NaOH soln and the aqueous extracts were acidified to pH <2 with
aq 6 M HCl soln. The resulting soln was extracted with EtOAc. The
organic phases were combined, dried, and concentrated in vacuo to
give acid (–)-10 (3.96 g, 91%) as a colorless oil.
[α]D25 –19.3 (c 1.0, CHCl3).
IR (neat): 3252, 3061, 1736, 1710, 1249, 1150 cm–1.
1H NMR (300 MHz, CDCl3): δ = 10.3 (br s, 1 H), 5.63 and 5.61
(AB, J = 2.1 Hz, 2 H), 4.52 (m, 1 H), 4.22 (m, 1 H), 2.51–2.49 (m,
2 H), 2.12 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 176.4 (C), 171.1 (C), 130.5 (C),
106.8 (CH2), 60.8 (CH2), 23.2 (CH), 21.7 (CH), 20.8 (CH3).
HRMS (ESI): m/z [M + H]+ calcd for C8H11O4: 171.0651; found:
171.0653.
(+)-(1R,2S)-2-(Azidocarbonyl)-3-methylenecyclopropylmethyl 
Acetate [(+)-11]
A soln of compound (–)-10 (500 mg, 2.93 mmol) was cooled at
0 °C, and oxalyl chloride (1.00 g, 5.86 mmol) was added. The soln
was allowed to warm to r.t. and stirred for 1 h. The soln was con-
centrated at reduced pressure and the resulting residue was taken up
in acetone (16 mL) and transferred dropwise to a vigorously stirred
soln of NaN3 (773.0 mg, 11.8 mmol) in H2O (35 mL) at 0 °C. The
resulting soln was maintained at 0 °C for 15 min, at which time it
was partitioned between EtOAc and H2O. After separation, the
aqueous layer was extracted with EtOAc and the combined organic
layers were washed with H2O and brine, and then dried (anhyd
MgSO4) and concentrated in vacuo to provide acyl azide (+)-11
(453.0 mg, 79%) as a colorless oil.
[α]D25 +29.0 (c 1.0, CHCl3).
IR (neat): 3064, 2132, 1749, 1238, 1157 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.60 and 5.58 (AB, J = 2.4 Hz, 2
H), 4.53 (m, 1 H), 4.16 (m, 1 H), 2.55–2.41 (m, 2 H), 2.04 (s, 3 H).
13C NMR (75 MHz, CDCl3): δ = 176.7 (C), 170.8 (C), 130.8 (C),
107.3 (CH2), 60.3 (CH2), 24.8 (CH), 24.1 (CH), 20.8 (CH3).
(+)-(1R,2S)-2-(tert-Butoxycarbonylamino)-3-methylenecyclo-
propylmethyl Acetate [(+)-13]
A soln of acyl azide (+)-11 (400 mg, 2.04 mmol) in benzene (20
mL) was heated at 75 °C until the evolution of gas ceased (~3 h),
and the mixture was cooled to r.t. The resulting isocyanate was dis-
solved in anhyd t-BuOH (2.0 mL) and the soln was refluxed for 4 h.
The mixture was cooled to r.t. and the solvent was removed in vac-
uo. The residue was purified by flash chromatography to give car-
bamate (+)-13 (395 mg, 75%) as a colorless oil.
[α]D25 +41.4 (c 1.0, CHCl3).
IR (neat): 3340, 3053, 1759, 1717, 1143 cm–1.
1H NMR (300 MHz, CDCl3): δ = 5.72 (s, 1 H), 5.55 (s, 1 H), 4.89
(br d, J = 5.9 Hz, 1 H), 4.18 and 4.03 (ABX, J = 10.7, 10.3, 5.5 Hz,
2 H), 3.35 (br s, 1 H), 2.11–2.07 (m, 1 H), 2.05 (s, 3 H), 1.44 (s, 9 H).
13C NMR (75 MHz, CDCl3): δ = 171.1 (C), 156.3 (C), 132.5 (C),
108.3 (CH2), 79.7 (C), 61.0 (CH2), 29.1 (CH), 27.8 (3 CH3), 21.3
(CH), 21.1 (CH3).
HRMS (ESI): m/z [M + H]+ calcd for C12H20O3N: 226.2965; found:
226.2970.
[2-(Hydromethyl)-3-methylenecyclopropylmethyl]ammonium 
Chloride (14)
A soln of (+)-13 (200.0 mg, 0.77 mmol) in aq 1.2 M HCl soln–gla-
cial AcOH (10 mL (1:1.5) was stirred at r.t. for 12 h. After removal
of the volatiles, the residue was triturated with Et2O. After filtration,
the solid residue was placed under vacuum and gave product 14
(89.6 mg, 85%) as a brown oil. The chlorohydrate salt 14 was suf-
ficiently pure to be used in the next step without purification.
IR (neat): 3386, 3296, 3058, 1247, 1172 cm–1.
1H NMR (300 MHz, MeOH-d4): δ = 4.32 (br s, 1 H), 4.17 (t, J = 2.0
Hz, 1 H), 2.41 (dd, J = 12.0, 4.7 Hz, 1 H), 2.16 (dd, J = 12.0, 7.0 Hz,
1 H), 1.76 (m, 1 H), 0.68–0.61 (m, 1 H).
13C NMR (75 MHz, MeOH-d4): δ = 129.9 (C), 110.7 (CH2), 59.4
(CH2), 28.3 (CH), 23.4 (CH).
HRMS (ESI): m/z [M]+ calcd for C5H10NO: 100.0757; found:
100.0753.
(+)-(1S,2S)-1-[2-(Hydromethyl)-3-methylenecyclopropyl]-1H-
pyrimidine-2,4-dione [(+)-16]
To a soln of chlorocarbonyl isocyanate (75.0 μL, 0.88 mmol) in
THF (2.0 mL) was slowly added a soln of ethyl vinyl ether (110 μL,
1.04 mmol) in THF (2.0 mL) at 0 °C. The resulting soln was stirred
for 20 min at 0 °C and Et3N (130 μL, 0.88 mmol) in THF (2.0 mL)
was then slowly added. The resulting suspension was stirred for 5
min at 0 °C then cooled down to –40 °C. A soln of chlorohydrate
salt 14 (100 mg, 0.74 mmol) in DMF (2.0 mL) was rapidly added to
the mixture and the suspension was allowed to slowly warm up to
r.t. Then, volatiles were evaporated and the residue was dissolved in
dioxane (5.0 mL). To this soln was added aq 0.5 M H2SO4 soln (9.0
mL) and the mixture was heated at 80 °C for 2 h. Then the soln was
cooled to r.t. and basified with aq 3 M NH3 soln (7.0 mL). The am-
monium salts were precipitated with MeOH and the suspension was
filtered. The filtrate was evaporated to dryness and the crude mate-
rial was purified by column chromatography to afford (+)-16 (107
mg, 75%) as a white solid; mp 183–184 °C.
[α]D25 +10.0 (c 1.0, MeOH).
IR (KBr): 3305, 3074, 1685, 1254, 1146 cm–1.
1H NMR (300 MHz, DMSO-d6): δ = 11.3 (s, 1 H), 7.51 (d, J = 7.9
Hz, 1 H), 6.02 (s, 1 H), 5.80 (s, 1 H), 5.51 (d, J = 7.9 Hz, 1 H), 4.56
(d, J = 5.6 Hz, 1 H), 3.82 (d, J = 7.8 Hz, 1 H), 3.39–3.18 (m, 2 H,
partially overlapped with DOH), 2.25–2.10 (m, 1 H).
13C NMR (75 MHz, DMSO-d6): δ = 163.0 (C), 151.4 (C), 144.1
(CH), 130.0 (C), 110.3 (CH2), 99.8 (CH), 57.3 (CH2), 33.7 (CH),
24.3 (CH).
HRMS (ESI): m/z [M + H]+ calcd for C9H11O3N2: 195.0760; found:
195.0760.
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